Goal. To study the e ffi cacy and safety of therapy with netakimab (NTK) and the complex drug — betamethasone dipropionate + betamesone phosphate (B) in patients with COVID-19 in outpatient settings.   Material and methods. A retrospective analysis of the treatment of 12 patients with severe new coronavirus infection who received therapy was performed simultaneously with netakimab (NTK) (the first administration at a dose of 60–120 mg, if indicated-the second administration at a dose of 60 mg) and a combined drug-betamethasone dipropionate + betamesone phosphate (B), at a dose of 2 ml o ffi cial solution. Treatment was performed at 7th (95% CI [6; 10]) day from the beginning of the disease. Repeated administration of NTK was performed in older patients due to insu ffi cient e ff ect of stopping hyperthermia and/or hypoxemia. A comprehensive examination of patients before and after NTK + B therapy was performed, which included clinical (assessment of the severity and duration of fever, analysis of gas exchange indicators), instrumental (computed tomography of the lungs) and laboratory methods, including determination of ferritin, IL-6.   Results. Simultaneous use of NTK + B therapy resulted in compensation of hyperthermia and/or SpO 2 > 93% 2.5 (95% CI [1; 3]) days after the first administration, a significant decrease in the level of inflammatory markers, and positive dynamics according to lung CT data. In all cases, increased respiratory support or additional antibiotic therapy, as well as hospitalization, were not required. The search for articles on the topic was carried out in the PubМed database in English and Russian, published in the period from 2001 to 2020.